Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyDavid M. Ross, Timothy P. Hughes, John F. Seymour et al.|Blood|2013Cited by 705
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line modelsFrançois‐Xavier Mahon, Junia V. Melo|Blood|2003Cited by 538